EGFR (A763_Y764insFHEA)

EGFR · Variant type: indel · HGVS: p.A763_Y764insFHEA

Drug response on this variant

#	Drug	Inhibition on variant	Residual	KISS
1	Osimertinib	99.9%	0.1%	97.24
2	Afatinib	99.8%	0.2%	98.50
3	Canertinib	99.8%	0.2%	96.49
4	Mobocertinib	99.5%	0.5%	97.22
5	Dacomitinib	99.2%	0.8%	97.99
6	Erlotinib	99.1%	0.9%	99.75
7	Neratinib	98.9%	1.1%	93.18
8	Ibrutinib	98.8%	1.2%	94.74
9	Lazertinib	98.5%	1.5%	97.47
10	Gefitinib	98.5%	1.5%	99.25
11	Bosutinib	98.4%	1.6%	87.22
12	Dasatinib	98.0%	2.0%	87.97
13	Vandetanib	97.8%	2.2%	95.74
14	Fostamatinib	97.7%	2.3%	96.74
15	Pralsetinib	97.0%	3.0%	93.43
16	Brigatinib	88.6%	11.4%	82.96
17	Alpelisib	86.0%	14.0%	97.22
18	Pacritinib	85.3%	14.8%	88.64
19	Lapatinib	83.3%	16.7%	99.25
20	Zanubrutinib	81.6%	18.4%	98.24
21	Ponatinib	68.5%	31.5%	78.23
22	Alectinib	51.4%	48.6%	95.49
23	Gilteritinib	50.3%	49.7%	88.97
24	Defactinib	49.8%	50.2%	92.68
25	Capmatinib	37.0%	63.0%	99.75

Positive Δ means the drug hits the variant harder than wild-type (mutation-selective); negative Δ means it loses potency (resistance).

Drug	Variant inh	WT inh	Δ (variant − WT)
Osimertinib	99.9%	99.1%	+0.8%
Afatinib	99.8%	100.0%	-0.2%
Canertinib	99.8%	98.4%	+1.3%
Mobocertinib	99.5%	100.0%	-0.5%
Dacomitinib	99.2%	99.8%	-0.6%
Erlotinib	99.1%	99.4%	-0.3%
Neratinib	98.9%	100.0%	-1.1%
Ibrutinib	98.8%	99.3%	-0.5%
Lazertinib	98.5%	100.0%	-1.5%
Gefitinib	98.5%	99.9%	-1.4%
Bosutinib	98.4%	99.3%	-0.9%
Dasatinib	98.0%	97.9%	+0.0%
Vandetanib	97.8%	99.3%	-1.5%
Fostamatinib	97.7%	97.8%	-0.0%
Pralsetinib	97.0%	99.1%	-2.2%
Brigatinib	88.6%	98.5%	-9.8%
Alpelisib	86.0%	—	—
Pacritinib	85.3%	—	—
Lapatinib	83.3%	99.2%	-15.8%
Zanubrutinib	81.6%	88.2%	-6.6%
Ponatinib	68.5%	—	—
Alectinib	51.4%	—	—
Gilteritinib	50.3%	91.0%	-40.8%
Defactinib	49.8%	94.6%	-44.8%
Capmatinib	37.0%	—	—

Loading…

Served from saifudeen2026@1.0.0 · API 0.1.0 · 11.5ms